Patent ID: 8747867

Claim:
A method of treating a subject having stage I non-small cell carcinoma (NSCLC) comprising: providing an assay sample obtained from said subject; determining the expression level in said sample of seven or more genes selected from E2F1, RRM2, MCM6, SF3B1, NUDCD1, HOXB7, SerpinB5, E2F4, HSPG2 and SCGB3A1; identifying a subject as having a poor prognosis based on the expression levels of said seven or more genes, wherein E2F1, RRM2, MCM6, SF3B1, NUDCD1, HOXB7, SerpinB5, E2F4 and HSPG2 expression levels are up-regulated, and SCGB3A1 expression level is down-regulated in patients with a poor prognosis; and treating the subject with a poor prognosis with an adjuvant therapy selected from chemotherapy, radiotherapy, immunotherapy and hormone therapy.